Legend Biotech (LEGN) Stock Forecast & Price Target

Legend Biotech Corp's strong outlook is bolstered by the Raritan expansion, which significantly enhances global capacity for the CARVYKTI therapy, positioning it to meet growing demand in earlier treatment lines. The company has successfully treated over 8,500 patients globally, with CARVYKTI demonstrating impressive growth metrics, including an anticipated peak sales potential of approximately $5 billion, driven by a year-over-year growth rate of 80% and a sequential growth rate of 19%, primarily from market share gains. Additionally, advancements in bridging therapies and improved management of adverse events are expected to strengthen CARVYKTI's competitive position in the market, further enhancing prospects for continued revenue growth.

Legend Biotech faces significant challenges that contribute to a negative outlook on its stock, primarily due to payor pushback against the pricing of its CAR-T treatment, Carvykti, which may decrease its overall market potential. The company is also grappling with competitive pressure from other clinical-stage CAR-T therapies, which could further limit long-term revenue opportunities. Additionally, various operational risks, including supply constraints, delays in pipeline advancements, and partnership uncertainties, compound concerns surrounding the company's ability to achieve sustained financial growth.